PIK3CA gene mutation and amplification are observed frequently in NPC, especially in advanced stages of disease [18], indicating a potential therapeutic effect of the dual PI3K/mTOR inhibitor in nasopharyngeal carcinoma. The gene discussed is PIK3CA; the disease is nasopharyngeal carcinoma.